Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. - Wikidata - awgldk - TriplyDB

Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.

Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.

http://www.wikidata.org/entity/Q37439463

about

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer Abiraterone in the treatment of metastatic castration-resistant prostate cancer Androgen receptor on the move: boarding the microtubule expressway to the nucleus Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases Chemotherapy and its evolving role in the management of advanced prostate cancer Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer Targeting the adaptive molecular landscape of castration-resistant prostate cancer Paclitaxel: new uses for an old drug.Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer Novel non-AR therapeutic targets in castrate resistant prostate cancer Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer.A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells.The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.Practical guide to the use of abiraterone in castration resistant prostate cancer.FOXO1: a potential target for human diseases Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions Preclinical profile of cabazitaxel.CYP17A1 inhibitors in castration-resistant prostate cancer FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer.A molecular analysis provides novel insights into androgen receptor signalling in breast cancer.Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer Emerging targeted therapies for castration-resistant prostate cancer.Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival Colchicine Significantly Reduces Incident Cancer in Gout Male Patients: A 12-Year Cohort Study.Horizon scanning for novel therapeutics for the treatment of prostate cancer.Broadening horizons in medical management of prostate cancer.Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting

P2860

Q24603649-713F5804-2148-4050-AA9D-8D96992ACD37 Q26773634-6C61E91A-ABDC-41A2-8CB7-91FDA8660270 Q26853635-A4D05B76-EFB5-4624-85EE-2B0D9EE1A979 Q26862560-53D970DD-3367-4377-BA60-E3BCEE70B2E5 Q26866135-F71BE475-A104-4E07-8C8F-043A53E8CAFC Q27008883-38BA38AF-2447-45DA-8B0B-2DE437770DCA Q27010542-391AA922-1969-4AE1-B079-AC39A6E52781 Q27022821-747B8937-E453-49B7-845F-6737A83B0A66 Q27691306-AE0E8FC7-F758-4C57-9B1A-8A28BE6457DC Q28075965-8F4907DF-8AAA-4D0F-9D83-41502930FD5D Q28076110-99EC5DA1-69FD-4BBD-8F17-2F2D63CF5CE3 Q28383663-F83B7DB2-4C6E-438D-BB9A-A6736A8E2B67 Q33621403-E28B9C34-C7B1-45FA-A791-B3AC39F2C7CC Q33775723-BF389F5D-4C74-4ABE-AD6E-F5AC28140F09 Q33775726-449B5021-4F73-4DEB-93C4-E16A9CFCBC27 Q33805953-99598026-7A9F-40BC-BE18-EEE1D7CB8AF1 Q33905704-5A2FD62A-81FA-4FA3-BF30-ABBB18633680 Q33946666-C9760A19-0E34-4086-BB41-9B3853CB9562 Q34070638-A5816CF7-D7C1-4D28-8C5D-A3D2E8CB5A12 Q34173809-46F7EE35-7A90-44BD-A048-5383E88A42E8 Q34250350-5759C2D3-BBCF-4699-B119-481A8779771F Q34296696-848C5866-4340-47A3-9846-26E8A45037F5 Q34324736-88FD9160-809A-419B-84A5-7CE5AB8B322F Q34394251-A7F760CE-A4DC-4173-8A92-893C9601F6B3 Q34456638-0B1AF455-A34C-4007-B352-131836B9D24F Q35024427-027300AF-5D81-40EB-B43E-EED4EDC4A934 Q35048550-088FDBEB-0A83-4CF1-8458-F905FF3892DD Q35189443-BDADCE33-455D-4235-8229-42F225760857 Q35609443-C8E7EE8D-1794-4FF2-91DC-6E04A6801B0D Q35611451-0239A27A-5CE9-4701-B63A-74AC6B0C4707 Q35956276-480F876D-B546-4A9E-A31A-6FA34903E09B Q35967139-99243655-BAA7-4BBE-9F00-AA83F424BF12 Q35999255-08016C3E-61D9-4C8D-B532-AA2101EB865A Q36414184-3239576F-5992-4D5C-A66C-8AE810A86986 Q36586089-B9F12984-B6E3-433C-9F28-9D006D1DFBA1 Q36909750-980BCCF1-BA23-46A4-8184-2A0ED2D09A9A Q37328209-A68AA9F0-E571-4202-B8A2-F7AFE0C495D1 Q37792060-EB4606EA-A8AA-4808-A569-FD3E6C1191D5 Q37878476-87CE6788-5044-472D-BB80-C4E53AB1EDC2 Q37952048-EEA6E91B-2E9E-492A-A4A2-0484D15D51D4

P2860

Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.

http://www.wikidata.org/entity/Q37439463

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Inhibition of the androgen rec ...... emotherapy in prostate cancer.

@en

Inhibition of the androgen rec ...... emotherapy in prostate cancer.

@nl

type

label

Inhibition of the androgen rec ...... emotherapy in prostate cancer.

@en

Inhibition of the androgen rec ...... emotherapy in prostate cancer.

@nl

prefLabel

Inhibition of the androgen rec ...... emotherapy in prostate cancer.

@en

Inhibition of the androgen rec ...... emotherapy in prostate cancer.

@nl

P1433

Q37439463-AE54A122-4BC3-4933-984C-230D725014B2

P1476

Q37439463-F83A4FCE-5915-4B17-ACAB-9ED09EAA6D72

P2093

Q37439463-1FF9744C-E4D8-4725-BC9F-D46DEC2243B4

Q37439463-29B80EBA-E5CF-418E-BBB6-2E1DEC1ADB69

Q37439463-2FBFF5D8-98D8-445D-B69D-DEF6F5474475

Q37439463-3FB207D4-A0D5-4037-B777-D862F9A1FE03

Q37439463-46036763-F53A-48A6-89B8-0E60A69CF586

Q37439463-CBB3C764-B783-49C8-BF30-246B6776D10A

Q37439463-DE7DD121-CF5D-49FC-AF0D-4F342A1691A9

Q37439463-F26F4458-232E-4055-AADA-2E9CCDD246EB

P2860

Q37439463-01EBD13D-1AA5-4B96-AD90-50A083B4C902

Q37439463-05B10C95-F979-44EC-82C1-ACB6F0947C67

Q37439463-1F063A12-84BE-472E-B496-42090657F829

Q37439463-29C1FE34-9D0D-487D-BE8C-4AC611ADDC10

Q37439463-32FDA56F-2117-4ABC-857E-26989B9E076B

Q37439463-3E8115C0-A6BB-43EA-B237-D886C52A7C54

Q37439463-4154C789-E2E2-4D7F-8454-C058D76EDA95

Q37439463-44229376-42E5-4BDB-9556-37FD8ED7BAB7

Q37439463-4C77352D-B530-49FF-9E48-427971CCE529

Q37439463-519C8BC4-E318-45D0-9FDD-DB93731B84F4

P304

Q37439463-1F6695AB-09AE-46BF-8885-31F2CD5AC2C6

P31

Q37439463-63131EC7-8A9C-4FBD-8CBF-CE3DCAC428AA

P356

Q37439463-0052FF89-7010-450E-B251-1BB25AFC94D1

P407

Q37439463-4D9644FB-84FD-4DE1-A750-602213F4F5A3

P433

Q37439463-0348446D-3848-4F97-B83D-15ED5069DB16

P478

Q37439463-7B663B73-6538-41A9-BA17-B29901CBD145

P577

Q37439463-75884439-59E7-41AE-88D2-986249590035

P5875

Q37439463-E786E624-0928-4EA0-9C7D-20DA91F61073

P698

Q37439463-605790D0-49DB-441B-85A6-51A2D7A1D7A5

P921

Q37439463-0B488DF6-85A6-4EA6-BD67-F9F342AF87A3

P932

Q37439463-ED110F02-E63A-4C17-A735-F7665979057F

P356

0008-5472.CAN-09-1504

P1433

Cancer Research

P1476

Inhibition of the androgen rec ...... emotherapy in prostate cancer.

@en

P2093

Akira Watahiki

http://www.w3.org/2001/XMLSchema#string

Haojie Huang

http://www.w3.org/2001/XMLSchema#string

Laura Bohrer

http://www.w3.org/2001/XMLSchema#string

Lu Gan

http://www.w3.org/2001/XMLSchema#string

Shuai Chen

http://www.w3.org/2001/XMLSchema#string

Yuwei Wang

http://www.w3.org/2001/XMLSchema#string

Yuzhuo Wang

http://www.w3.org/2001/XMLSchema#string

Zhen Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor

FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines

Molecular determinants of resistance to antiandrogen therapy

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Paclitaxel in the treatment of hormone-refractory prostate cancer.

Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.

Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.

Androgen receptor signaling in androgen-refractory prostate cancer.

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers.

P304

8386-8394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-1504

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26891656

http://www.w3.org/2001/XMLSchema#string

P698

19826044

http://www.w3.org/2001/XMLSchema#string

P921

P932

2783542

http://www.w3.org/2001/XMLSchema#string